BIIB logo

BIIB
Biogen Inc

18,677
Mkt Cap
$31.02B
Volume
566,362.00
52W High
$185.17
52W Low
$110.04
PE Ratio
16.61
BIIB Fundamentals
Price
$182.09
Prev Close
$181.94
Open
$182.07
50D MA
$153.78
Beta
0.66
Avg. Volume
1.76M
EPS (Annual)
$11.19
P/B
1.47
Rev/Employee
$1.22M
Loading...
Loading...
News
all
press releases
Biogen, Eisai File In Japan To Make Leqembi A Weekly At-Home Alzheimer's Shot
Eisai files for Japan approval of a weekly at-home Leqembi injection, offering an alternative to IV dosing and aiming to streamline Alzheimer's care.read more...
Benzinga·10h ago
News Placeholder
More News
News Placeholder
Franklin Resources Inc. Has $28.76 Million Holdings in Biogen Inc. $BIIB
Franklin Resources Inc. decreased its stake in shares of Biogen Inc. (NASDAQ:BIIB - Free Report) by 61.1% during the 2nd quarter, according to the company in its most recent filing with the SEC. The...
MarketBeat·17h ago
News Placeholder
Biogen Inc. $BIIB Shares Acquired by Charles Schwab Investment Management Inc.
Charles Schwab Investment Management Inc. boosted its stake in Biogen Inc. (NASDAQ:BIIB - Free Report) by 5.5% in the second quarter, according to the company in its most recent disclosure with the...
MarketBeat·20h ago
News Placeholder
Magnetar Financial LLC Sells 5,235 Shares of Biogen Inc. $BIIB
Magnetar Financial LLC reduced its position in Biogen Inc. (NASDAQ:BIIB - Free Report) by 67.8% in the second quarter, according to the company in its most recent Form 13F filing with the Securities...
MarketBeat·2d ago
News Placeholder
Prudential Financial Inc. Lowers Stock Holdings in Biogen Inc. $BIIB
Prudential Financial Inc. lowered its position in shares of Biogen Inc. (NASDAQ:BIIB - Free Report) by 7.8% in the 2nd quarter, according to the company in its most recent Form 13F filing with the...
MarketBeat·3d ago
News Placeholder
Biogen Inks Research Deal With Dayra to Boost Immunology Pipeline
BIIB's research deal with Dayra targets oral macrocyclic peptides to advance its immunology pipeline and expand next-generation therapies.
Zacks·4d ago
News Placeholder
Why Is Biogen Stock Trading Higher After Semaglutide Alzheimer's Data?
Biogen stock rises as Novo Nordisk's Alzheimer's trials disappoint, spotlighting Leqembi's role and a new immunology collaboration with Dayra Therapeutics.read more...
Benzinga·4d ago
News Placeholder
J. L. Bainbridge & Co. Inc. Has $15.37 Million Stock Holdings in Biogen Inc. $BIIB
J. L. Bainbridge & Co. Inc. decreased its position in Biogen Inc. (NASDAQ:BIIB - Free Report) by 1.7% during the 2nd quarter, according to the company in its most recent disclosure with the...
MarketBeat·5d ago
News Placeholder
Biogen, Dayra Therapeutics Partner To Develop Oral Macrocyclic Peptides For Immunological Diseases
(RTTNews) - Biogen Inc. (BIIB) said Monday that it has entered into a partnership with Dayra Therapeutics to discover and develop oral macrocyclic peptides for immunological conditions...
Nasdaq News: Markets·5d ago
News Placeholder
Entropy Technologies LP Decreases Stake in Biogen Inc. $BIIB
Entropy Technologies LP trimmed its holdings in shares of Biogen Inc. (NASDAQ:BIIB - Free Report) by 54.7% during the second quarter, according to the company in its most recent Form 13F filing with...
MarketBeat·5d ago

Latest BIIB News

View

Advertisement|Remove ads.

Advertisement|Remove ads.